- Thomson Reuters StreetEvents via Yahoo FinanceMay 27 9:58 AM
Lastly, we appreciate the generous support of the California Institute for Regenerative Medicine or CIRM, whose grant funding has helped not only to advance the clinical development of ...
MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic ArthritisMarket Watch2 days ago
- Bristol Herald Courier7 days ago
... Analysis, Segmentation, Size, Share, Trend, Future Demand and Leading Players Updates by Forecast to 2025 by 360 Research ReportsMarket Watch2 days ago
- Thomson Reuters StreetEvents via Yahoo FinanceJun 12 21:04 PM
Moving now...that by the end of 2019, there will be 3 ENHANZE-based products in Phase 3 clinical testing. These include Janssen's DARZALEX, Roche's fixed-dose combination of Perjeta and ...
- Thomson Reuters StreetEvents via Yahoo FinanceJun 12 14:56 PM
With our partnership with Janssen, we've seen 2 significant events. We've entered Phase I/IIa for our HPV vaccine, treating chronically infected women to prevent cervical cancer. And ...
- related to Janssen Research & Development, LLC